Professor Sir Mike Stratton is Director of the Wellcome Trust Sanger Institute. He qualified in medicine at Oxford University and Guy’s Hospital, trained as a histopathologist and obtained a PhD in the molecular biology of cancer at the Institute of Cancer Research, London.
His primary research interests have been in the genetics of cancer. His early work focused on inherited susceptibility. He mapped and identified the major high risk breast cancer susceptibility gene BRCA2 and subsequently a series of moderate risk breast cancer and other cancer susceptibility genes.
In 2000 he initiated the Cancer Genome Project at the Wellcome Trust Sanger Institute which conducts systematic genome-wide searches for somatic mutations in human cancer. Through these studies he discovered somatic mutations of the BRAF gene in malignant melanoma and several other mutated cancer genes in breast, lung, renal, bone, myeloid malignancies and other cancers. He has described the basic patterns of somatic mutation in cancer genomes revealing underlying DNA mutational and repair processes.
He is a Fellow of the Royal Society (FRS) and was Knighted in the Queen’s birthday honours in 2013.